Visual Improvement in an Aniridic Patient Following Topical Acetylcholinesterase Inhibition: Evidence Against a Purely Pinhole Mechanism

Introduction

The prevailing explanation for visual improvement associated with topical cholinergic agents has been induction of miosis and the resulting increase in depth of focus. This optical effect, analogous to viewing through a pinhole aperture, reduces blur circles and may improve visual acuity in selected patients.

However, acetylcholine is also a major neurotransmitter within the retina and central visual system.^3-8 Cholinergic signaling influences contrast sensitivity, receptive-field organization, signal amplification, visual attention, and ganglion cell output.^3-8 Experimental studies have demonstrated that acetylcholine plays a critical role in retinal information processing through interactions among amacrine, bipolar, and ganglion cells.^3-7 In many retinal degenerations, significant portions of the inner retinal circuitry remain anatomically preserved despite progressive photoreceptor loss.⁷

The observations described herein arose during the development of topical cholinergic therapy for presbyopia, which led to the first patented physiologic/pharmacologic treatment for age-related loss of near vision.¹ During that work, unexpected visual improvement was observed in several patients with concurrent retinal disease, prompting further investigation into potential retinal and neural effects of cholinergic modulation.^1,2

This report describes an aniridic patient who experienced substantial visual improvement following topical acetylcholinesterase inhibition.^1,2 Because the affected eye lacked an iris and therefore could not undergo miosis, the case provides a unique opportunity to examine whether visual improvement can occur independently of a pinhole mechanism.

Historical Context

This case was identified during an exploratory clinical treatment series conducted between 1999 and 2001 involving 29 consecutive patients (34 eyes) with diverse retinal disorders, including dry and wet age-related macular degeneration, retinal vascular occlusion, diabetic retinopathy, macular hole, solar retinopathy, and inherited retinal disease.^1,2

The retinal investigation evolved in parallel with the development of topical cholinergic therapy for presbyopia, which resulted in the first patented physiologic and pharmacologic method for the treatment of age-related loss of near vision.¹ During that work, unexpected visual improvements were observed in several patients with coexisting retinal disease, prompting a separate exploratory evaluation of cholinergic modulation in retinal disorders for which no effective restorative therapies were available at the time.^1,2

The primary objective of the retinal series was to determine whether topical acetylcholinesterase inhibition could improve visual function beyond the optical effects traditionally attributed to cholinergic-induced miosis. During the course of the investigation, several unexpected observations emerged, including bilateral improvement following unilateral treatment, prolonged visual benefit exceeding the anticipated pharmacologic duration of the drug, persistence of visual gains despite pharmacologic reversal of miosis, and improvement in an eye with complete surgical aniridia.^1,2

Among all patients in the series, the aniridic patient represented a unique mechanistic control because the absence of the iris eliminated the possibility that visual improvement could be attributed to pupillary constriction or a pinhole effect. Consequently, this case became central to the development of the hypothesis that topical cholinergic therapy may influence visual function through neural mechanisms in addition to optical effects.^3-8

Case Report

Among the 29 patients enrolled in the 1999 - 2001 exploratory retinal treatment series, Patient 29 was of particular interest because complete unilateral aniridia provided a natural mechanistic control for evaluating the role of miosis in treatment response.¹

The patient was pseudophakic with asymmetric dry AMD. The left eye had complete surgical aniridia resulting from a complicated cataract extraction in the mid-1970s followed by secondary sulcus-fixated intraocular lens implantation in the late 1980s.

Baseline visual acuity measured approximately 20/30−1 in the right eye and 20/100 in the left eye. Pinhole acuity in the left eye improved only to approximately 20/70−1. Near visual acuity in the left eye measured approximately 20/70.

Topical echothiophate iodide 0.30% was administered at bedtime.^1,2 Treatment was initially unilateral and later extended bilaterally. Follow-up examinations were performed over a two-month period.

After one week of treatment, visual acuity in the aniridic eye improved to approximately 20/70 and remained stable at one month. Following bilateral treatment, additional improvement was documented at two months. Distance visual acuity improved to approximately 20/25 in the right eye and 20/50 in the left eye. Near visual acuity in the aniridic eye improved from approximately 20/70 to 20/30.

The patient reported improved functional vision in daily activities. Throughout the observation period, the left eye remained completely aniridic, eliminating any possibility of treatment-induced pupillary constriction.

Discussion

This case provides evidence that visual improvement associated with topical acetylcholinesterase inhibition cannot always be attributed solely to a pinhole effect.

The central observation is that the aniridic eye demonstrated meaningful improvement in both distance and near visual acuity despite complete absence of the iris. Because miosis was anatomically impossible, the conventional explanation of enhanced depth of focus through pupillary constriction cannot adequately account for the observed response.

Several additional observations from the original treatment series further support a physiologic mechanism.^1,2 Visual benefit frequently persisted beyond the expected pharmacologic duration of the drug. Improvement was observed bilaterally following unilateral treatment. Visual gains also persisted despite pharmacologic redilation with phenylephrine 10% or tropicamide administered after treatment. Collectively, these findings are difficult to reconcile with a purely optical explanation.

Current understanding of retinal neurobiology provides a biologically plausible alternative mechanism.^3-8 Acetylcholine is released by specialized retinal amacrine cells and modulates signal transmission throughout the inner retina.^3-7 Cholinergic pathways influence contrast sensitivity, gain control, receptive-field organization, and ganglion cell output. Importantly, in many outer retinal disorders, including AMD, substantial portions of the inner retinal circuitry remain structurally preserved despite loss of photoreceptors and retinal pigment epithelium.⁷

Inhibition of acetylcholinesterase increases acetylcholine availability within these surviving neural networks.³ Enhanced cholinergic transmission may improve the efficiency with which degraded photoreceptor signals are processed and transmitted to higher visual centers.^4-6 Such modulation could potentially amplify residual visual information and improve functional vision despite irreversible outer retinal pathology.

The bilateral improvement observed following unilateral treatment raises the possibility that both retinal and central nervous system mechanisms contribute to the response.^4-6 Cholinergic pathways are known to influence cortical attention, perceptual processing, and visual learning, suggesting that retinal and central effects may act synergistically.

Alternative explanations, including placebo response, spontaneous fluctuation, or measurement variability, cannot be completely excluded. Nevertheless, the unique absence of an iris provides an unusually informative mechanistic control that directly challenges the hypothesis that miosis alone accounts for visual improvement following cholinergic therapy.

The observations should be considered hypothesis-generating rather than definitive. However, they support further prospective investigation into cholinergic modulation as a means of enhancing function within surviving retinal and visual pathways.^3-8

Conclusions

An aniridic patient with dry AMD demonstrated substantial improvement in both distance and near visual acuity following topical acetylcholinesterase inhibition.^1,2 Because the affected eye lacked an iris and could not undergo miosis, the findings argue against a purely optical pinhole mechanism. The observations support the hypothesis that cholinergic modulation may enhance visual function through retinal and possibly central neural pathways.^3-8 Further investigation is warranted to determine whether pharmacologic enhancement of surviving neural circuits may represent a therapeutic strategy for retinal degenerative disease.

Financial Support

None

Conflict of Interest

The author declares no proprietary or commercial interest in any material discussed in this article.

Patient Consent

Patient consent was obtained for use of de-identified clinical information. No identifying information is included in this report.

Data Availability

Data supporting the findings of this report are available from the corresponding author upon reasonable request.

References

1. Nolan GM. Methods for Treating Various Eye Disorders. US Patent 6,273,092 B1. 2001.
2. Nolan GM. Method of Treating Certain Eye Diseases. US Patent 6,605,640 B2. 2003.
3. Neal MJ, Cunningham JR. Modulation of retinal neurotransmission by acetylcholine. Prog Retin Eye Res. 1995.
4. Sarter M, Hasselmo ME, Bruno JP, Givens B. Unraveling the attentional functions of cortical cholinergic inputs. Brain Res Brain Res Rev. 2005.
5. Disney AA, Aoki C, Hawken MJ. Gain modulation by cholinergic pathways in visual cortex. Neuron. 2007.
6. Rokem A, Silver MA. Cholinergic enhancement augments visual perceptual learning. J Neurosci. 2010.
7. Masland RH. The neuronal organization of the retina. Neuron. 2012.
8. Vaney DI, Sivyer B, Taylor WR. Direction selectivity in the retina: circuitry and function. Prog Retin Eye Res. 2012.